文献速递认知障碍与谵妄多重用药

曲唑酮与非典型抗精神病药用于老年出院后谵妄的安全性比较

Safety outcomes of trazodone versus antipsychotics for delirium after hospital admission in adults aged 65 years and older: a nationwide cohort study using a target trial emulation framework.
PubMed 文献 · Lancet Healthy Longev · 2025-12-22

该全国性队列研究采用目标试验模拟框架,纳入65岁以上无精神疾病、出院30天内新处方曲唑酮或非典型抗精神病药的谵妄患者,比较出院后安全结局。结果显示曲唑酮与较低的全因再住院、谵妄再住院、尿路感染和全因死亡风险相关,跌倒、肺炎和卒中风险无显著差异。

要点

  • 与利培酮和奥氮平相比再住院风险降低,与喹硫平相比无差异。

核心结论

  • 曲唑酮相比非典型抗精神病药与较低的再住院和全因死亡风险相关,可能是出院后谵妄相关症状管理的更安全替代。

研究设计与样本

  • 基于美国Medicare(2013–2022年)和Optum Clinformatics数据库(2013–2025年)的全国性队列研究,采用目标试验模拟框架。
  • 纳入65岁以上无精神疾病、出院30天内新处方曲唑酮或非典型抗精神病药(喹硫平、利培酮或奥氮平)且有谵妄诊断的住院患者。
  • 使用倾向评分重叠加权调整162个协变量,采用Fine-Gray模型和Cox模型估计关联,两数据库结果用逆方差加权合并。

临床怎么用

  • 对于出院后谵妄相关症状的老年患者,曲唑酮可作为非典型抗精神病药的潜在更安全替代选择。
  • 选择具体药物时需注意,曲唑酮相对利培酮和奥氮平在再住院风险上更优,但相对喹硫平未见差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trazodone has emerged as a potentially safer alternative to atypical antipsychotic medications for managing delirium-related symptoms in older adults after hospital admission. This study aimed to compare safety outcomes in older adults who were prescribed trazodone versus atypical antipsychotic medication after hospital discharge. METHODS: This population-based cohort study was done using US Medicare data from Jan 1, 2013, to Dec 31, 2022, and Optum de-identified Clinformatics Data Mart Database data from Jan 1, 2013, to Aug 31, 2025, with a target trial emulation framework. Patients aged at least 65 years without psychiatric disorders who were prescribed a new trazodone or atypical antipsychotic medication (quetiapine, risperidone, or olanzapine) prescription within 30 days of hospital discharge with a claims-based delirium diagnosis were included. We applied propensity score overlap weighting to adjust for 162 covariates. The primary outcome was all-cause rehospitalisation. Secondary outcomes included rehospitalisation for delirium, falls (including fall-related emergency department visits), pneumonia, urinary tract infections, stroke, and all-cause mortality. Treatment-outcome associations were estimated using the Fine-Gray model for non-fatal outcomes (presented as subdistribution hazard ratio [SDHR]) and the Cox model for all-cause mortality (presented as hazard ratio [HR]). Estimates from the two databases were pooled using inverse-variance weighting. FINDINGS: 11 678 trazodone and 29 590 atypical antipsychotic medication users were included. Compared with antipsychotic medications, trazodone was associated with lower risks of rehospitalisation (SDHR 0·95 [95% CI 0·91-0·98]), rehospitalisation for delirium (SDHR 0·80 [0·75-0·86]), urinary tract infection (SDHR 0·84 [0·72-0·99]), and all-cause mortality (HR 0·84 [0·79-0·90]); no significant difference was observed for falls (SDHR 0·93 [0·85-1·02]), pneumonia (SDHR 0·96 [0·79-1·16]), and stroke (SDHR 0·92 [0·77-1·11]). The reduced risk of rehospitalisation with trazodone was consistent when compared with risperidone (SDHR 0·89 [0·84-0·95]), and olanzapine (SDHR 0·88 [0·82-0·94]) but no difference was seen with quetiapine (SDHR 0·97 [0·93-1·01]). INTERPRETATION: These results revealed reduced risks of rehospitalisation and all-cause mortality associated with trazodone versus atypical antipsychotic medications. Trazodone is a potentially safer alternative to antipsychotic medications in the management of delirium-related symptoms after hospital discharge. FUNDING: National Institute on Aging.

来源:Lancet Healthy Longev,查看原文。版权归原作者所有。

引用

  1. Yang CT, Wilkins JM, Pritchard KT, et al. Safety outcomes of trazodone versus antipsychotics for delirium after hospital admission in adults aged 65 years and older: a nationwide cohort study using a target trial emulation framework. Lancet Healthy Longev. 2025. PMID: 41448219. doi:10.1016/j.lanhl.2025.100804

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。